Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern

• Published in: ESMO open Vol. 7; no. 5; p. 100574
• Main Authors: Lasagna, A., Bergami, F., Lilleri, D., Percivalle, E., Quaccini, M., Serra, F., Comolli, G., Sarasini, A., Sammartino, J.C., Ferrari, A., Arena, F., Secondino, S., Cicognini, D., Schiavo, R., Lo Cascio, G., Cavanna, L., Baldanti, F., Pedrazzoli, P., Cassaniti, I.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.10.2022; The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology
• Subjects: Antibodies, Neutralizing; Antibodies, Viral; BNT162 Vaccine; BNT162b2 anti-SARS-CoV-2 vaccine; cancer; COVID-19 - prevention & control; COVID-19 Vaccines - pharmacology; Humans; Immunity, Cellular; Immunoglobulin G; Longitudinal Studies; mRNA Vaccines; Neoplasms - drug therapy; neutralizing antibody; Original Research; Oxygen; SARS-CoV-2; third dose; Viral Vaccines - genetics; VOCs; VOCs; neutralizing antibody; BNT162b2 anti-SARS-CoV-2 vaccine; cancer; third dose

The role and the durability of the immunogenicity of the third dose of vaccine against COVID-19 variants of concern in cancer patients have to be elucidated. We have prospectively evaluated the immunogenicity of the third dose of the SARS-CoV-2 BNT162b2 messenger RNA vaccine in triggering both humor...